Ruimin Hong Selected Research

Hematologic Neoplasms (Hematological Malignancy)

4/2024	A rare KMT2A::CBL transcript in an acute monoblastic leukemia patient with an unfavorable outcome.
3/2024	Cytokine-based models for efficient differentiation between infection and cytokine release syndrome in patients with hematological malignancies.
1/2022	CAR-T cell therapy-related cytokine release syndrome and therapeutic response is modulated by the gut microbiome in hematologic malignancies.
1/2021	Tumor Burden Measured by 18F-FDG PET/CT in Predicting Efficacy and Adverse Effects of Chimeric Antigen Receptor T-Cell Therapy in Non-Hodgkin Lymphoma.
1/2021	New-Onset Severe Cytopenia After CAR-T Cell Therapy: Analysis of 76 Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ruimin Hong Research Topics

Disease

7	Neoplasms (Cancer) 04/2024 - 01/2021
5	Hematologic Neoplasms (Hematological Malignancy) 04/2024 - 01/2021
5	Cytokine Release Syndrome 03/2024 - 01/2021
5	Multiple Myeloma 01/2023 - 01/2021
3	Leukemia 04/2024 - 01/2022
3	Infections 04/2024 - 01/2023
3	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2021 - 10/2020
2	Cytopenia 01/2023 - 01/2021
2	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2022 - 01/2021
1	Disease Progression 04/2024
1	Fever (Fevers) 03/2024
1	Carcinogenesis 06/2023
1	B-Cell Lymphoma (Lymphoma, B Cell) 01/2023
1	Critical Illness (Critically Ill) 01/2023
1	T-Cell Lymphoma (Lymphoma, T Cell) 01/2023
1	Residual Neoplasm 01/2023
1	Lymphoma (Lymphomas) 01/2021
1	COVID-19 01/2021
1	Cauda Equina Syndrome 01/2021
1	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2021
1	Composite Lymphoma 01/2018

Drug/Important Bio-Agent (IBA)

16	Chimeric Antigen ReceptorsIBA 04/2024 - 10/2020
3	CytokinesIBA 03/2024 - 01/2021
3	B-Cell Maturation AntigenIBA 01/2023 - 01/2021
3	bis(3- bis(4- chlorophenyl)methyl- 4- dimethylaminophenyl)amineIBA 01/2022 - 01/2021
2	Biomarkers (Surrogate Marker)IBA 01/2021 - 01/2021
1	Proteins (Proteins, Gene)FDA Link 04/2024
1	Lysine (L-Lysine)FDA Link 04/2024
1	MethyltransferasesIBA 04/2024
1	tocilizumab (atlizumab)FDA Link 06/2023
1	HLA Antigens (Human Leukocyte Antigens)IBA 01/2023
1	Circulating Tumor DNAIBA 01/2021
1	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 01/2021
1	NF-kappa B (NF-kB)IBA 01/2021
1	Interleukin-10 (Interleukin 10)IBA 01/2021
1	Lenalidomide (CC 5013)FDA Link 01/2021
1	Interleukin-6 (Interleukin 6)IBA 01/2021

Therapy/Procedure

14	Therapeutics 04/2024 - 01/2018
3	Hematopoietic Stem Cell Transplantation 04/2024 - 01/2018
3	Drug Therapy (Chemotherapy) 04/2024 - 01/2018
2	Immunotherapy 01/2022 - 01/2021
1	Aftercare (After-Treatment) 01/2023
1	Immunomodulation 01/2018